Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage-Reference-Cited by-同舟云学术

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage

Published:2018-10-05 Issue:6410 Volume:362 Page:91-95
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Park Jung Wook¹^ORCID,Lee John K.²,Sheu Katherine M.³^ORCID,Wang Liang¹,Balanis Nikolas G.³,Nguyen Kim⁴,Smith Bryan A.¹,Cheng Chen⁵,Tsai Brandon L.¹,Cheng Donghui¹,Huang Jiaoti⁶^ORCID,Kurdistani Siavash K.⁵⁷⁸⁹^ORCID,Graeber Thomas G.³⁷⁸⁹¹⁰^ORCID,Witte Owen N.¹³⁷⁸⁹

Affiliation:

1. Department of Microbiology, Immunology, and Molecular Genetics, University of California–Los Angeles, Los Angeles, CA 90095, USA.

2. Division of Hematology and Oncology, Department of Medicine, University of California–Los Angeles, Los Angeles, CA 90095, USA.

3. Department of Molecular and Medical Pharmacology, University of California–Los Angeles, Los Angeles, CA 90095, USA.

4. Department of Ecology and Evolutionary Biology, University of California–Los Angeles, Los Angeles, CA 90095, USA.

5. Department of Biological Chemistry, University of California–Los Angeles, Los Angeles, CA 90095, USA.

6. Department of Pathology, School of Medicine, Duke University, Durham, NC 27710, USA.

7. Molecular Biology Institute, University of California–Los Angeles, Los Angeles, CA 90095, USA.

8. Jonsson Comprehensive Cancer Center, University of California–Los Angeles, Los Angeles, CA 90095, USA.

9. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California–Los Angeles, Los Angeles, CA 90095, USA.

10. Crump Institute for Molecular Imaging, University of California–Los Angeles, Los Angeles, CA 90095, USA.

Abstract

Some (re)programming notes on cancer Epithelial cancers develop resistance to targeted therapies in a number of different ways. Several cancer types do so by undergoing phenotypic conversion to a highly aggressive cancer called small cell neuroendocrine carcinoma (SCNC). Whether distinct cancer types accomplish this “reprogramming” through the same mechanism has been unclear. Park et al. show that the same set of oncogenic factors transforms both normal lung and normal prostate epithelial cells into SCNCs that resemble clinical samples (see the Perspective by Kareta and Sage). This convergence of molecular pathways could potentially simplify the development of new therapies for SCNC, which is currently untreatable. Science , this issue p. 91 ; see also p. 30

Funder

National Institutes of Health

American Cancer Society

National Cancer Institute

W.M. Keck Foundation

Hal Gaba Fund for Prostate Cancer Research

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. Hallmarks of Cancer: The Next Generation